Literature DB >> 1912553

P53 gene mutations in acute myeloid leukemia with 17p monosomy.

P Fenaux1, P Jonveaux, I Quiquandon, J L Laï, J M Pignon, M H Loucheux-Lefebvre, F Bauters, R Berger, J P Kerckaert.   

Abstract

We looked for mutations of exons 5 to 8 of the P53 gene in 10 patients with acute myeloid leukemia (AML) and 17p monosomy, and 36 patients with AML and no cytogenetic abnormalities of 17p. DNA was analyzed by polymerase chain reaction, single-strand conformation polymorphism analysis, and nucleotide sequencing. Four of the 10 patients with 17p monosomy showed point mutation, single-nucleotide deletion, or insertion in exons 7 or 8. By contrast, only 1 of the 36 patients with AML and no cytogenetic abnormalities of 17p showed a mutation of the P53 gene in exons 5 to 8 (P less than .01). These results suggest that alterations of the P53 gene may have a role in leukemogenesis in some cases of AML. The fact that P53 gene mutations occurred more often in patients with 17p monosomy seems to support the "recessive" model of tumor suppressive activity of the P53 gene rather than the "dominant" model, in which alteration of only one allele is sufficient for the development of malignancy.

Entities:  

Mesh:

Year:  1991        PMID: 1912553

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

Authors:  Krzysztof Mrózek
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

2.  Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Authors:  Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; Mercedes Garayoa; Diego Fernández-Lázaro; Maria-Belen Vidriales; Carlos M Galmarini; Pablo Avilés; Carmen Cuevas; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

3.  The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin gene expression.

Authors:  D J Law; S A Tarlé; J L Merchant
Journal:  Mamm Genome       Date:  1998-02       Impact factor: 2.957

4.  Translational regulation of human p53 gene expression.

Authors:  L Fu; M D Minden; S Benchimol
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

5.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.

Authors:  Jianting Long; Brian Parkin; Peter Ouillette; Dale Bixby; Kerby Shedden; Harry Erba; Shaomeng Wang; Sami N Malek
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

6.  A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations.

Authors:  J S Beck; A E Kwitek; P H Cogen; A K Metzger; G M Duyk; V C Sheffield
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

7.  p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.

Authors:  M Kitagawa; S Yoshida; T Kuwata; T Tanizawa; R Kamiyama
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

8.  Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.

Authors:  Haiming Xu; Silvia Menendez; Brigitte Schlegelberger; Narae Bae; Peter D Aplan; Gudrun Göhring; Tony R Deblasio; Stephen D Nimer
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

9.  Analysis of the p53 gene mutations in acute myelogenous leukemia: the p53 gene mutations associated with a deletion of chromosome 17.

Authors:  M Kurosawa; M Okabe; Y Kunieda; M Asaka
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

10.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.